PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-26.68%
Both companies show declining cash positions (-26.68% vs TRAW's -18.04%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-26.68%
Cash + STI yoy 1.25-1.5x TRAW's -18.04%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.50%
Above 1.5x TRAW's -2.20%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-27.05%
0.75-0.9x TRAW's -31.18%. Bill Ackman would ask if competitor is building short-term resources more aggressively.
-7.44%
Below half TRAW's 5300.00%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRAW and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
12.75%
Higher Other Non-Current Assets Growth compared to TRAW's zero value, indicating worse performance.
-5.69%
Below half of TRAW's 35.10%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-25.21%
0.75-0.9x TRAW's -30.01%. Bill Ackman questions if competitor invests more aggressively for growth.
9.15%
Less than half of TRAW's -4.76%. David Dodd sees a more disciplined AP approach or lower volume.
-74.86%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-9.15%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
No Data
No Data available this quarter, please select a different quarter.
7.01%
Less than half of TRAW's -6.27%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.56%
Similar yoy to TRAW's -12.15%. Walter Schloss sees parallel expansions in long-term liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.31%
Less than half of TRAW's -8.23%. David Dodd sees far fewer liability expansions relative to competitor.
1.65%
Less than half of TRAW's 36.67%. David Dodd sees fewer share issuances vs. competitor.
-3.34%
≥ 1.5x TRAW's -1.17%. David Dodd sees higher yoy retained profits than competitor.
-6.51%
Less than half of TRAW's -92.86%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.72%
1.25-1.5x TRAW's -32.89%. Bruce Berkowitz notes an above-average equity expansion.
-25.21%
0.75-0.9x TRAW's -30.01%. Bill Ackman wonders if competitor invests or leverages more aggressively.
-100.00%
Both TRAW and the company show zero Total Investments Growth.
-11.75%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
27.85%
Above 1.5x TRAW's 18.04%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.